查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1679375

肺腺癌治疗市场规模、份额、趋势分析报告：按疗法、最终用途、地区和细分市场预测，2025-2030 年

Lung Adenocarcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Immunotherapy, Radiation Therapy), By End-use (Hospitals, Specialty Clinics), By Region (North America, Europe), And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

肺腺癌治疗市场的成长和趋势

根据Grand View Research, Inc.的最新报告，全球肺腺癌治疗市场预计到2030年将达到111.8亿美元，2025年至2030年期间的复合年增长率为10.7%。

该市场提供广泛的治疗方案、技术和服务，旨在管理和治疗肺腺癌（非小细胞肺癌（NSCLC）的一种亚型）。

某些地区吸烟率的上升、空气污染和职业危害等环境因素是市场成长的主要驱动力。随着越来越多的人被诊断出患有肺腺癌，对有效治疗方案的需求也在增加。

人们对肺癌症状和风险因素的认识不断提高，对市场产生了重大影响。旨在提高戒烟和早期发现意识的公共卫生宣传活动导致越来越多的人在出现症状后儘快寻求医疗帮助。

2023年10月，百时美施贵宝以每股58美元收购了Mirati，股权总价值为48亿美元，潜在价值为58亿美元，包括或有价值权，其中包括用于治疗晚期非小细胞肺癌的KRASG12C抑制剂KRAZATI（adagrasib）。

肺腺癌治疗市场报告重点

  • 化疗部分在 2024 年占据了最大的收入份额，为 36%。这主要归功于其在肺癌治疗中的既定作用和治疗方法的持续进步。
  • 预计免疫疗法领域将成长最快，预测期内复合年增长率为 13.5%。肺腺癌盛行率的不断上升推动了对先进治疗方案的需求，这些方案与化疗和放射线治疗等传统治疗方法相比，具有更好的疗效和安全性。
  • 医院凭藉其完善的基础设施和提供多种先进癌症治疗的能力，在 2024 年占据了最大的收益占有率，达到 63.9%。
  • 预计专科诊所部门在预测期内将以最快的复合年增长率成长。这一增长是由个人化和标靶治疗治疗的需求不断增长，以及患者对肺癌治疗方案的认识不断提高所推动的。
  • 由于肺腺癌发病率上升以及对创新治疗方法的高度重视，北美肺腺癌治疗市场在 2024 年将占据最大的收入份额，为 39.5%。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章肺腺癌治疗市场变数、趋势和范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 分析——波特五力分析
    • PESTLE分析
    • 管道分析

第四章肺腺癌治疗市场：治疗业务分析

  • 2024年和2030年的治疗市场占有率
  • 治疗细分仪表板
  • 2018 年至 2030 年按疗法分類的市场规模、预测与趋势分析
  • 化疗
  • 标靶治疗
  • 免疫疗法
  • 放射线治疗
  • 其他的

5. 肺腺癌治疗市场-最终用途业务分析

  • 2024 年及 2030 年终端用途市场占有率
  • 最终用途细分仪表板
  • 2018 年至 2030 年按最终用途分類的市场规模、预测和趋势分析
  • 医院
  • 专科门诊
  • 其他的

第六章肺腺癌治疗市场：按地区估计和趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 2018-2030年市场规模及预测趋势分析
  • 北美洲
    • 2018-2030年各国情况
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 2018-2030年各国情况
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 丹麦
    • 瑞典
  • 亚太地区
    • 按国家/地区，2018 年至 2030 年
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 2018-2030年各国情况
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 2018-2030年各国情况
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争格局

  • 参与者概述
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • Pfizer Inc.
    • AstraZeneca
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • Boehringer Ingelheim International GmbH
    • Novartis AG
    • Merck KGaA（EMD Serono）
    • AbbVie Inc.
    • Astellas Pharma Inc.
    • F. Hoffmann-La Roche Ltd
Product Code: GVR-4-68040-428-6

Lung Adenocarcinoma Treatment Market Growth & Trends:

The global lung adenocarcinoma treatment market size is expected to reach USD 11.18 billion by 2030, registering a CAGR of 10.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. This market offers a range of therapeutic options, technologies, and services aimed at managing and treating lung adenocarcinoma, which is a subtype of non-small cell lung cancer (NSCLC).

The rise in smoking rates in certain regions and environmental factors such as air pollution and occupational hazards are key growth drivers for market growth. As more individuals are diagnosed with lung adenocarcinoma, there is a corresponding demand for effective treatment options.

Increased awareness about lung cancer symptoms and risk factors has significantly influenced the market. Public health campaigns aimed at educating populations about smoking cessation and early detection led to more individuals seeking medical attention sooner after experiencing symptoms.

In October 2023, Bristol Myers Squibb acquired Mirati for USD 58.00 per share, totaling USD 4.8 billion in equity value, potentially rising to USD 5.8 billion with contingent value rights, including KRAZATI (adagrasib), a KRASG12C inhibitor for advanced non-small cell lung cancer.

Lung Adenocarcinoma Treatment Market Report Highlights:

  • The chemotherapy segment accounted for the largest revenue share of 36% in 2024. This is primarily due to its established role in lung cancer management and ongoing advancements in treatment regimens.
  • The immunotherapy segment is expected to witness the fastest growth, with a projected CAGR of 13.5% over the forecast period. The rising prevalence of lung adenocarcinoma has increased the demand for advanced treatment options that offer better efficacy and safety compared to traditional therapies such as chemotherapy and radiation.
  • Hospitals accounted for the largest revenue share of 63.9% in 2024, driven by their comprehensive infrastructure and ability to provide a wide range of advanced cancer treatments.
  • The specialty clinics segment is expected to grow at the fastest CAGR over the forecast period. This growth is driven by the rising demand for personalized and targeted therapies, along with increasing patient awareness of lung cancer treatment options.
  • North America lung adenocarcinoma treatment market held the largest revenue share of 39.5% in 2024, driven by the rising incidence of lung adenocarcinoma and a strong focus on innovation in treatment approaches.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. End use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Lung Adenocarcinoma Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis

Chapter 4. Lung adenocarcinoma treatment market: Type Business Analysis

  • 4.1. Treatment Market Share, 2024 & 2030
  • 4.2. Treatment Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
  • 4.4. Chemotherapy
    • 4.4.1. Chemotherapy Market, 2018 - 2030 (USD Million)
  • 4.5. Targeted therapy
    • 4.5.1. Targeted Therapy Market, 2018 - 2030 (USD Million)
  • 4.6. Immunotherapy
    • 4.6.1. Immunotherapy Market, 2018 - 2030 (USD Million)
  • 4.7. Radiation therapy
    • 4.7.1. Radiation Therapy Market, 2018 - 2030 (USD Million)
  • 4.8. Other
    • 4.8.1. Other Market, 2018 - 2030 (USD Million)

Chapter 5. Lung adenocarcinoma treatment market: End use Business Analysis

  • 5.1. End Use Market Share, 2024 & 2030
  • 5.2. End Use Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 5.4. Hospitals
    • 5.4.1. Hospitals Market, 2018 - 2030 (USD Million)
  • 5.5. Specialty Clinics
    • 5.5.1. Specialty Clinics Market, 2018 - 2030 (USD Million)
  • 5.6. Other
    • 5.6.1. Other Market, 2018 - 2030 (USD Million)

Chapter 6. Lung adenocarcinoma treatment market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030
  • 6.4. North America
    • 6.4.1. North America Lung Adenocarcinoma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Regulatory Framework
      • 6.4.2.3. Competitive Insights
      • 6.4.2.4. U.S. Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Regulatory Framework
      • 6.4.3.3. Competitive Insights
      • 6.4.3.4. Canada Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Regulatory Framework
      • 6.4.4.3. Competitive Insights
      • 6.4.4.4. Mexico Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Lung Adenocarcinoma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Competitive Insights
      • 6.5.2.4. UK Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Competitive Insights
      • 6.5.3.4. Germany Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Competitive Insights
      • 6.5.4.4. France Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Regulatory Framework
      • 6.5.5.3. Competitive Insights
      • 6.5.5.4. Italy Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Regulatory Framework
      • 6.5.6.3. Competitive Insights
      • 6.5.6.4. Spain Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Norway
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Regulatory Framework
      • 6.5.7.3. Competitive Insights
      • 6.5.7.4. Norway Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Denmark
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Regulatory Framework
      • 6.5.8.3. Competitive Insights
      • 6.5.8.4. Denmark Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Sweden
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Regulatory Framework
      • 6.5.9.3. Competitive Insights
      • 6.5.9.4. Sweden Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Lung Adenocarcinoma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Competitive Insights
      • 6.6.2.4. Japan Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Competitive Insights
      • 6.6.3.4. China Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Competitive Insights
      • 6.6.4.4. India Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. South Korea
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Competitive Insights
      • 6.6.5.4. South Korea Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Australia
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Competitive Insights
      • 6.6.6.4. Australia Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Competitive Insights
      • 6.6.7.4. Thailand Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Lung Adenocarcinoma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Competitive Insights
      • 6.7.2.4. Brazil Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Competitive Insights
      • 6.7.3.4. Argentina Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8. MEA
    • 6.8.1. MEA Lung Adenocarcinoma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Competitive Insights
      • 6.8.2.4. South Africa Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Framework
      • 6.8.3.3. Competitive Insights
      • 6.8.3.4. Saudi Arabia Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Framework
      • 6.8.4.3. Competitive Insights
      • 6.8.4.4. UAE Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Regulatory Framework
      • 6.8.5.3. Competitive Insights
      • 6.8.5.4. Kuwait Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Pfizer Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. AstraZeneca
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Bristol-Myers Squibb Company
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Eli Lilly and Company
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Boehringer Ingelheim International GmbH
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Novartis AG
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Merck KGaA (EMD Serono)
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. AbbVie Inc.
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Astellas Pharma Inc.
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. F. Hoffmann-La Roche Ltd
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global lung adenocarcinoma treatment market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 5 Global lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 6 North America lung adenocarcinoma treatment market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 8 North America lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 9 U.S. lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 10 U.S. lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Canada lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 12 Canada lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 13 Mexico lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 14 Mexico lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 15 Europe lung adenocarcinoma treatment market, by country, 2018 - 2030 (USD Million)
  • Table 16 Europe lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 17 Europe lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 18 UK lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 19 UK lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 20 Germany lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 21 Germany lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 22 France lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 23 France lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 24 Italy lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 25 Italy lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 26 Spain lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 27 Spain lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Norway lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 29 Norway lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 30 Denmark lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 31 Denmark lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 32 Sweden lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 33 Sweden lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific lung adenocarcinoma treatment market, by country, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 37 Japan lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 38 Japan lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 39 China lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 40 China lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 41 India lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 42 India lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 43 Australia lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 44 Australia lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 45 South Korea lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 46 South Korea lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 47 Thailand lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 48 Thailand lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 49 Latin America lung adenocarcinoma treatment market, by country, 2018 - 2030 (USD Million)
  • Table 50 Latin America lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 51 Latin America lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 52 Brazil lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 53 Brazil lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 54 Argentina lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 55 Argentina lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa lung adenocarcinoma treatment market, by country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 59 South Africa lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 60 South Africa lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 63 UAE lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 64 UAE lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 65 Kuwait lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 66 Kuwait lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Lung Adenocarcinoma Treatment Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Treatment and end use outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Lung adenocarcinoma treatment market dynamics
  • Fig. 12 Lung adenocarcinoma treatment market: Porter's five forces analysis
  • Fig. 13 Lung adenocarcinoma treatment market: PESTLE analysis
  • Fig. 14 Lung adenocarcinoma treatment market: Treatment segment dashboard
  • Fig. 15 Lung adenocarcinoma treatment market: Treatment market share analysis, 2024 & 2030
  • Fig. 16 Chemotherapy market, 2018 - 2030 (USD Million)
  • Fig. 17 Targeted therapy market, 2018 - 2030 (USD Million)
  • Fig. 18 Immunotherapy market, 2018 - 2030 (USD Million)
  • Fig. 19 Radiation therapy market, 2018 - 2030 (USD Million)
  • Fig. 20 Other market, 2018 - 2030 (USD Million)
  • Fig. 21 Lung adenocarcinoma treatment market: End use segment dashboard
  • Fig. 22 Lung adenocarcinoma treatment market: End use market share analysis, 2024 & 2030
  • Fig. 23 Hospitals market, 2018 - 2030 (USD Million)
  • Fig. 24 Specialty clinics market, 2018 - 2030 (USD Million)
  • Fig. 25 Other market, 2018 - 2030 (USD Million)
  • Fig. 26 Lung Adenocarcinoma Treatment Market revenue, by region
  • Fig. 27 Regional marketplace: Key takeaways
  • Fig. 28 North America lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. country dynamics
  • Fig. 30 U.S. lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 31 Canada country dynamics
  • Fig. 32 Canada lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 33 Mexico country dynamics
  • Fig. 34 Mexico lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 35 Europe lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 36 UK country dynamics
  • Fig. 37 UK lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 38 Germany country dynamics
  • Fig. 39 Germany lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 40 France country dynamics
  • Fig. 41 France lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 42 Italy country dynamics
  • Fig. 43 Italy lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 44 Spain country dynamics
  • Fig. 45 Spain lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 46 Norway country dynamics
  • Fig. 47 Norway lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 48 Sweden country dynamics
  • Fig. 49 Sweden lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 50 Denmark country dynamics
  • Fig. 51 Denmark lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 52 Asia Pacific lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 53 Japan country dynamics
  • Fig. 54 Japan lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 55 China country dynamics
  • Fig. 56 China lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 57 India country dynamics
  • Fig. 58 India lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 59 Australia country dynamics
  • Fig. 60 Australia lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 61 South Korea country dynamics
  • Fig. 62 South Korea lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 63 Thailand country dynamics
  • Fig. 64 Thailand lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 65 Latin America lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 66 Brazil country dynamics
  • Fig. 67 Brazil lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 68 Argentina country dynamics
  • Fig. 69 Argentina lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 70 MEA lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 71 South Africa country dynamics
  • Fig. 72 South Africa lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 73 Saudi Arabia country dynamics
  • Fig. 74 Saudi Arabia lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 75 UAE country dynamics
  • Fig. 76 UAE lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 77 Kuwait country dynamics
  • Fig. 78 Kuwait lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 79 Company categorization
  • Fig. 80 Company market position analysis
  • Fig. 81 Strategic framework